Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
about
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancerPulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.Gemcitabine in metastatic breast cancer.Docetaxel in the treatment of breast cancer: current experience and future prospects.Gemcitabine and taxanes in metastatic breast cancer: a systematic review.
P2860
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Front-line chemotherapy with d ...... a multicenter phase II study.
@ast
Front-line chemotherapy with d ...... a multicenter phase II study.
@en
type
label
Front-line chemotherapy with d ...... a multicenter phase II study.
@ast
Front-line chemotherapy with d ...... a multicenter phase II study.
@en
prefLabel
Front-line chemotherapy with d ...... a multicenter phase II study.
@ast
Front-line chemotherapy with d ...... a multicenter phase II study.
@en
P2093
P2860
P356
P1433
P1476
Front-line chemotherapy with d ...... a multicenter phase II study.
@en
P2093
Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG)
Ch Christophilakis
Ch Kouroussis
D Mavroudis
I Varthalitis
K Kalbakis
N Androulakis
P2860
P304
P356
10.1159/000081325
P577
2004-01-01T00:00:00Z